Prudential PLC vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Prudential PLC trades at $23.82 (market cap $28.84B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.51 (market cap $2.27B). The key difference: Prudential PLC is far larger — about 12.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Prudential PLC pays a 2.33% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| PUK | SLS | |
|---|---|---|
Market Cap | $28.84B | $2.27B |
Volume | 3,531,298 | 4,179,659 |
Sector | Financials | Health |
52-Week High | $33.61 | $15.46 |
52-Week Low | $23.54 | $1.39 |
Typical Hold Time | 119 Days | — |
Enterprise Value | $28.38B | $2.14B |
Dividend Yield | 2.33% | — |
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.54, down 4.31% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent news highlights strategic moves including the sale of its Alexforbes stake and a rebranding of its wealth management unit. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook is mixed: solid fundamentals and growth initiatives support upside, but technical weakness and earnings volatility pose risks. Investment opportunity lies in the attractive valuation (P/E 8.4) and strategic focus, countered by bearish momentum and competitive pressures in insurance markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →